prednisolone has been researched along with Myeloproliferative Disorders in 13 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient was treated with prednisolone (0·5-1 mg/kg/day) for more than 20 weeks under the impression of hypereosinophilic syndrome, but without improvement of leucocytosis and eosinophilia." | 7.76 | A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone. ( Gau, JP; Hsiao, LT; Liu, CY; Pai, JT; Teng, HW; Tzeng, CH; Wang, JR; Yen, CC, 2010) |
| "We encountered a male patient with marked basophilia and eosinophilia complicated by anemia, thrombocytopenia, myelofibrosis, and hyperhistaminemia." | 7.69 | A patient with basophilic-eosinophilic myeloproliferative disorder showing monosomy 7 and hyperhistaminemia. ( Hayashi, Y; Imanaka, F; Shindo, H; Takimoto, Y, 1997) |
| " The patient was treated with prednisolone (0·5-1 mg/kg/day) for more than 20 weeks under the impression of hypereosinophilic syndrome, but without improvement of leucocytosis and eosinophilia." | 3.76 | A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone. ( Gau, JP; Hsiao, LT; Liu, CY; Pai, JT; Teng, HW; Tzeng, CH; Wang, JR; Yen, CC, 2010) |
| "We encountered a male patient with marked basophilia and eosinophilia complicated by anemia, thrombocytopenia, myelofibrosis, and hyperhistaminemia." | 3.69 | A patient with basophilic-eosinophilic myeloproliferative disorder showing monosomy 7 and hyperhistaminemia. ( Hayashi, Y; Imanaka, F; Shindo, H; Takimoto, Y, 1997) |
| "Prednisolone was added if there was no response after 3 months in cohort 1 and based on up-front randomization in cohort 2 if there was no response at 3 or 6 months." | 2.84 | Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. ( Benner, A; Blau, IW; Döhner, H; Döhner, K; Gattermann, N; Grießhammer, M; Hebart, H; Heidel, FH; Hochhaus, A; Jost, E; Kreipe, H; Platzbecker, U; Reiter, A; Schafhausen, P; Schlenk, RF; Stegelmann, F; Teleanu, V; Verbeek, W; Waller, C; Werner, M, 2017) |
| "The clinical course suggests that the pneumonitis was induced by hydroxycarbamide." | 2.58 | A 66-year-old man with hydroxycarbamide induced pneumonitis. ( Derichs, C; Klooster, P; Vlasveld, LT, 2018) |
| "Oral prednisolone treatment improved the pulmonary nodular lesion, the abnormal laboratory data, and the uveitis." | 1.31 | [A case of pulmonary inflammatory pseudotumor with hypergammaglobulinemia, elevated ANA, and uveitis]. ( Gejyo, F; Kaizu, C; Kuwabara, K; Moriyama, H; Saito, Y; Suzuki, E; Takada, T; Terada, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Derichs, C | 1 |
| Klooster, P | 1 |
| Vlasveld, LT | 1 |
| Olivieri, A | 1 |
| Cimminiello, M | 1 |
| Corradini, P | 1 |
| Mordini, N | 1 |
| Fedele, R | 1 |
| Selleri, C | 1 |
| Onida, F | 1 |
| Patriarca, F | 1 |
| Pavone, E | 1 |
| Svegliati, S | 1 |
| Gabrielli, A | 1 |
| Bresciani, P | 1 |
| Nuccorini, R | 1 |
| Pascale, S | 1 |
| Coluzzi, S | 1 |
| Pane, F | 1 |
| Poloni, A | 1 |
| Olivieri, J | 1 |
| Leoni, P | 1 |
| Bacigalupo, A | 1 |
| Koudoukpo, C | 1 |
| Jachiet, M | 1 |
| Zini, JM | 1 |
| Andreoli, A | 1 |
| Pinquier, L | 1 |
| Rybojad, M | 1 |
| Bosset, D | 1 |
| de Masson, A | 1 |
| Bagot, M | 1 |
| Lebbé, C | 1 |
| Bouaziz, JD | 1 |
| Schlenk, RF | 1 |
| Stegelmann, F | 1 |
| Reiter, A | 1 |
| Jost, E | 1 |
| Gattermann, N | 1 |
| Hebart, H | 1 |
| Waller, C | 1 |
| Hochhaus, A | 1 |
| Platzbecker, U | 1 |
| Schafhausen, P | 1 |
| Blau, IW | 1 |
| Verbeek, W | 1 |
| Heidel, FH | 1 |
| Werner, M | 1 |
| Kreipe, H | 1 |
| Teleanu, V | 1 |
| Benner, A | 1 |
| Döhner, H | 1 |
| Grießhammer, M | 1 |
| Döhner, K | 1 |
| Wang, JR | 1 |
| Yen, CC | 1 |
| Gau, JP | 1 |
| Hsiao, LT | 1 |
| Liu, CY | 1 |
| Pai, JT | 1 |
| Tzeng, CH | 1 |
| Teng, HW | 1 |
| Sawada, T | 1 |
| Adachi, Y | 1 |
| Ishii, Y | 1 |
| Yasui, H | 1 |
| Arimura, Y | 1 |
| Endo, T | 1 |
| ROTHERMUNDT, A | 1 |
| Miyazawa, K | 1 |
| Kakazu, N | 1 |
| Ohyashiki, K | 1 |
| Shenoy, RD | 1 |
| Bhat, KG | 1 |
| Kamath, N | 1 |
| Kumble, Y | 1 |
| Chandran, G | 1 |
| Ahern, MJ | 1 |
| Seshadri, P | 1 |
| Coghlan, D | 1 |
| Takimoto, Y | 1 |
| Imanaka, F | 1 |
| Hayashi, Y | 1 |
| Shindo, H | 1 |
| Hagiwara, S | 1 |
| Yuo, A | 1 |
| Miwa, A | 1 |
| Takezako, N | 1 |
| Hirano, N | 1 |
| Togawa, A | 1 |
| Kaizu, C | 1 |
| Takada, T | 1 |
| Moriyama, H | 1 |
| Terada, M | 1 |
| Suzuki, E | 1 |
| Gejyo, F | 1 |
| Kuwabara, K | 1 |
| Saito, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-Center Phase II Study With Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage[NCT00949364] | Phase 2 | 103 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for prednisolone and Myeloproliferative Disorders
| Article | Year |
|---|---|
A 66-year-old man with hydroxycarbamide induced pneumonitis.
Topics: Administration, Oral; Aged; Disease Progression; Dose-Response Relationship, Drug; Drug Administrati | 2018 |
2 trials available for prednisolone and Myeloproliferative Disorders
| Article | Year |
|---|---|
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Autoantibodies; Benzamides; Chronic Disease; Disease-F | 2013 |
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Topics: Aged; Aged, 80 and over; Alleles; Biomarkers; Chromosome Banding; Female; Humans; Immunologic Factor | 2017 |
10 other studies available for prednisolone and Myeloproliferative Disorders
| Article | Year |
|---|---|
[Urticarial vasculitis associated with essential thrombocythaemia progressing to myelofibrosis].
Topics: Bone Marrow; Drug Therapy, Combination; Fatal Outcome; Humans; Janus Kinase 2; Male; Middle Aged; Mu | 2014 |
A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
Topics: Adult; Antineoplastic Agents, Hormonal; Benzamides; Drug Therapy, Combination; Eosinophilia; Eosinop | 2010 |
Esophageal lesions in myeloproliferative neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Esophageal Neopl | 2012 |
[MASSIVE CELL INFILTRATION OF THE PULMONARY PARENCHYMA IN ALEUKEMIC CHRONIC MYELOSIS].
Topics: Humans; Leukemia; Leukemia, Myeloid; Lung; Lung Diseases; Myeloproliferative Disorders; Pathology; P | 1964 |
Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
Topics: Adrenal Cortex Hormones; Adult; Aged; Bone Marrow; Eosinophilia; Female; Fibrosis; Humans; Hypereosi | 2007 |
Transient myeloproliferative disorder and eosinophilic pericardial effusion in a down syndrome neonate.
Topics: Antineoplastic Agents, Hormonal; Down Syndrome; Eosinophils; Humans; Infant, Newborn; Male; Myelopro | 2008 |
Rheumatic manifestations of the myelodysplastic syndromes: a comparative study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Diagnosis, Differential; Female; Humans; Male; My | 1996 |
A patient with basophilic-eosinophilic myeloproliferative disorder showing monosomy 7 and hyperhistaminemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arabinonucleotides; Basophils; Chromos | 1997 |
A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological re
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin | 1998 |
[A case of pulmonary inflammatory pseudotumor with hypergammaglobulinemia, elevated ANA, and uveitis].
Topics: Administration, Oral; Antibodies, Antinuclear; Chronic Disease; Glaucoma; Humans; Hypergammaglobulin | 2001 |